Sermorelin

Compound background

Sermorelin (GRF 1‑29) acetate is a bioactive, 29‑amino‑acid fragment of endogenous growth‑hormone‑releasing hormone (GHRH) that retains full affinity for pituitary GHRH receptors, triggering a physiological pulse of growth hormone (GH) and subsequent hepatic IGF‑1 production. In clinical and pre‑clinical studies, intravenous or subcutaneous sermorelin produced dose‑dependent GH peaks comparable to endogenous nocturnal bursts, with rapid clearance (t½ ≈ 10–12 min) that minimizes receptor desensitization. Randomized trials in children with isolated GH deficiency demonstrated improved linear growth velocity, while adult studies documented enhanced fat‑free mass and maintenance of normal cortisol, prolactin, and thyroid axes—underscoring its selectivity for the somatotropic pathway. Because sermorelin acts upstream at the hypothalamic–pituitary level, negative‑feedback mechanisms preserve physiologic GH ceilings, providing a valuable tool for probing GH‑IGF‑1 dynamics, age‑related somatopause, and metabolic modulation in animal and human research models.

Quality standards

• Greater than 99% pure

Sourcing standards

• Raw ingredients manufactured by an FDA registered & audited supplier following cGMP standards
• Finished peptides 0.22 µm sterile-filtered (aseptically processed) and produced in a GMP facility
• Tested by a US FDA registered & audited third-party analytical lab accredited by ISO/IEC and U.S. Department of Ecology

Learn more about Peptidology product sourcing, testing and quality standards.

Analytical reports

Batch 1359 – Sermorelin 99.8% 10.60 mg